Anzeige
Mehr »
Freitag, 11.07.2025 - Börsentäglich über 12.000 News
Der nächste Volltreffer direkt neben einer brandneuen Entdeckung! Kupfer im Höhenflug!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EP67 | ISIN: US31573L1052 | Ticker-Symbol: SG0
Tradegate
10.07.25 | 14:59
0,560 Euro
+0,90 % +0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FIBROBIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
FIBROBIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5250,53521:26
0,5250,53521:16
ACCESS Newswire
170 Leser
Artikel bewerten:
(1)

RedChip Companies, Inc.: Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / July 11, 2025 / RedChip Companies will air interviews with Brag House Holdings, Inc. (NASDAQ:TBH) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, July 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

  • TBH:https://www.redchip.com/assets/access/tbh_access

  • FBLG: https://www.redchip.com/assets/access/fblg_access

In an exclusive interview, Lavell Juan Malloy II, CEO and Co-Founder of Brag House, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss how Brag House is redefining brand engagement for Gen Z through its social gaming and data-driven platform. Malloy highlights the Company's unique ability to connect brands with the highly sought-after Gen Z demographic by fusing college sports rivalries, casual gaming, and community-based interaction into a seamless digital experience. With proven success through partnerships with Coca-Cola, McDonald's, the Denver Broncos, and Learfield, Brag House delivers industry-leading engagement metrics-including CPC and CPM rates significantly below industry averages. Malloy also outlines the Company's strategic alliance with Learfield, powering Brag's national expansion across over 200+ universities, and shares insights into Brag's multi-tiered monetization model and scalable B2B data solutions-positioning the Company at the convergence of three massive markets: gaming, advertising, and analytics.

Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.

TBH and FBLG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Brag House

Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. For more information, visit www.braghouse.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/brag-house-and-fibrobiologics-interviews-to-air-on-the-redchip-s-1047720

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.